is there an ideal space for allogeneic car-t products for myeloma?
Published 1 year ago • 56 plays • Length 4:12Download video MP4
Download video MP3
Similar videos
-
4:34
what is the future for car-t in multiple myeloma?
-
12:26
what is an allogeneic car t cell?
-
7:01
idecabtagene vicleucel for myeloma: karmma study results and real-world evidence
-
8:14
bispecific versus car t-cell therapy for myeloma and bridging therapy needs for car-t
-
6:52
who is the right patient for car-t therapy?
-
3:47
what is car t-cell therapy?
-
0:46
who is eligible for car-t therapy?
-
5:15
car-t for myeloma: where are we now and where are we going?
-
2:43
where does car-t fit in the myeloma treatment algorithm?
-
57:44
understanding car t cell therapy for the treatment of lymphoma
-
1:02:12
recent advances & new opportunities in blood cancer research & treatment
-
1:02:26
myeloma care: pharmacy perspectives on antibodies and bcma car-t
-
1:26:24
the car-t revolution 3 years after fda approval
-
31:12
car t-cell innovation - matthew frigault, md
-
4:17
car-t cell therapy cilta-cel for relapsed/refractory myeloma | doris hansen, md | asco 2023
-
1:21
exploring the future of car t-cell therapy in multiple myeloma
-
3:31
will car t-cell therapy be approved for earlier lines of myeloma treatment?
-
1:01:47
understanding car t cell therapy and lymphoma | lrf webinars
-
47:35
top doctor & patient talk game changing cancer treatments: how close is a cure? (multiple myeloma)